NCT07036237

Brief Summary

Briefly, 105 teeth with symptomatic irreversible pulpitis will be included in the study and randomly allocated to three groups (A, B and C). Pre-Operative pain score using VAS will be taken after which root canal treatment shall be initiated. Group A (35 teeth) will receive normal saline as a final irrigant. 35 teeth each of Groups B and C will receive Dexamethasone and Tramadol Solutions, respectively as final irrigants. Post-operative pain scores will be recorded after 6, 12, 24 and 48 hours after the procedure. Statistical analysis will be performed using SPSS version 26.0. Mean comparison of pre-treatment and post-treatment VAS scores will be done by repeated measure two-way ANOVA. Post-hoc LSD test will be applied for pairwise comparison within and/or between groups. The sample size of 105 subjects (35 including 5 as a drop out per group) is calculated using PASS version 15, based on two sample proportion with 95% confidence of interval and 80% power of test, no pain in dexamethasone (81.7%) and drug2

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
105

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 4, 2025

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

May 15, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

June 25, 2025

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 17, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 17, 2025

Completed
Last Updated

June 25, 2025

Status Verified

June 1, 2025

Enrollment Period

9 months

First QC Date

May 15, 2025

Last Update Submit

June 24, 2025

Conditions

Keywords

Opiod analgesicsRoot Canal IrrigantSymptomatic Irreversible PulpitisSIPVisual Analoque ScaleVAS

Outcome Measures

Primary Outcomes (1)

  • Post-Operative Pain intensity

    Measurement Tool : Visual Analogue Scale (VAS) Unit Of Measure : Pain intensity will be assessed on a 0-10 scale, where 0 represents no pain and 10 represents the worst pain imaginable.

    6 to 48 hours

Study Arms (3)

Tramadol Group

EXPERIMENTAL

Group A 30 participants will receive Tramadol as part of root canal treatment.

Drug: Dexamethasone Group

dexamethasone group

EXPERIMENTAL

Dexamehasone as a final irrigant

Drug: Tramadol group

Normal Saline group

PLACEBO COMPARATOR

normal saline as a final irrigant

Drug: Tramadol groupDrug: Dexamethasone Group

Interventions

Drug used as final irrigant

Also known as: Drug A
Normal Saline groupdexamethasone group

drug used as a final irrigant

Also known as: Drug B
Normal Saline groupTramadol Group

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • ASA 1 and ASA 2 eligible patients
  • Patients aged between 18 and 50 years
  • Mandibular Single rooted teeth diagnosed with symptomatic irreversible pulpitis
  • Preoperative pain measured with the help of visual analogue scale and

You may not qualify if:

  • Patients who have taken any analgesic at least 12 hours before the procedure
  • Teeth diagnosed with pulpal necrosis and periradicular periodontitis
  • Teeth non restorable due to any reason,
  • Root canal calcifications and resorptions.
  • Women with breast feeding and pregnancy
  • Patients allergic to any of the two drugs shall also be excluded from the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

DIOKHS,Dow University Of Health Sciences

Karachi, Sindh, KARACHI WEST, Pakistan

Location

Study Officials

  • Muhammad AM Amin, FCPS

    Dow University of Health Sciences

    STUDY CHAIR
  • Fazal FM Qazi, FCPS

    Dow University of Health Sciences

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Patients included in the study will pick an envelope A, B or C for inclusion in the Group A, B or C. Researcher will himself be responsible for randomization and recruitment of participants into groups. In this Double blinded study neither clinician or patient will not know the drug of the envelope and the syringes will be masked by white paper labeled A, B and C by the dental assistant.
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MDS Trainee Of Operative Dentistry, Dow University Of Health Sciences

Study Record Dates

First Submitted

May 15, 2025

First Posted

June 25, 2025

Study Start

March 4, 2025

Primary Completion

November 17, 2025

Study Completion

November 17, 2025

Last Updated

June 25, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will share

Study will be published in a recongnized Journal to share with other researchers

Shared Documents
STUDY PROTOCOL
Time Frame
2to3years
Access Criteria
Journal

Locations